![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Friday, July 26, 2019 10:33:33 AM
1. I need to wait for the published results on mPFS. It doesn’t make sense to me to have a vast improvement in mOS without a corresponding improvement in mPFS. If the GBM dynamics under DCVax-L is according to the model you suggested, then mOS should be the primary and possibly the only endpoint, imo. The team should have a dynamicist who should model the progression under DCVax-L administration. It is not essential, but at least that would be interesting to me.
There is a possibility that the unblinded treatment mPFS and mOS will be statistically significantly better than the mPFS and mOS of the placebo/control arm. However, I will not bet on it. Remember that the blinded and blended post surgical mOS was only 23.1 months and we have to subtract about 3 months from that to obtain the post enrollment mOS. That is not a great result and may also be reflected by the mPFS of treatment vs. placebo/control which may or may not show SS differences favoring the treatment arm.
Having said that, there is little doubt in my mind that 25%PFS and 25%OS for the treatment arm are home runs in that they will be impressive on their own as well as significantly better than placebo/control.
Remember that according to the report of February 2017, roughly 36 months after the midpoint surgery and 33 months after midpoint enrollment, about 25% of the trial was still PFS. I have not come across trials with a similar GBM population where 1/4 of the trial still demonstrated PFS after 33 months post enrollment. I will also not be surprised if 25% of the treatment arm will still be alive beyond 4 years and more than 20% survive past the 5 year timeline.
I believe that in this trial it is all about the tail and the mOS and mPFS will not have great significance. The importance of a long thick surviving tail may have forced NWBO to compose a new, hitherto unconventional SAP which may explain why it has been taking over 6 months to do just that.
Recent NWBO News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/13/2024 08:01:24 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2024 09:06:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/08/2024 08:30:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/02/2024 02:42:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/30/2024 11:49:38 PM
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
Alliance Creative Group (ACGX) Releases Q2 2024 Financial and Disclosure Report with an increase of over $130,000 in Net Income from Q2 2023 to Q2 2024 • ACGX • Aug 14, 2024 8:30 AM
Avant Technologies Unveils AI-Powered Healthcare Infrastructure to Deliver Intelligent Healthcare Solutions • AVAI • Aug 14, 2024 8:00 AM
SANUWAVE Announces Record Quarterly Revenues: Q2 FY2024 Financial Results • SNWV • Aug 13, 2024 7:11 AM
Kona Gold Beverages, Inc. Nears Completion of Reverse Merger with New Candidate • KGKG • Aug 12, 2024 10:00 AM
Maybacks Global Entertainment and DigiTrax Entertainment Sign Agreement to Broadcast "Karaoke Cloud" on iDreamCTV • AHRO • Aug 12, 2024 8:45 AM
HealthLynked Partners with RxSpark to Enhance Medication Access and Management for Patients • HLYK • Aug 12, 2024 8:00 AM